Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A phase III randomized double-blind placebo-controlled study of MTS004 in pseudobulbar affect secondary to neurological disease
CTR20223145Phase 3Completed
- Sponsor
- Jitai Pharmaceutical
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in emotional lability (PBA) comparing MTS004 oral disintegrating tablet with Placebo oral disintegrating tablet (2 arms). Primary endpoint: Reduction in PBA episode frequency at 12 weeks. Started Jan 2023; status: completed.
02
Drugs
MTS-004
03
Conditions
emotional lability (PBA)
Beyond the preview
Go deeper on CTR20223145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223145.